Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Corcept Therapeutics ( (CORT) ) has issued an update.
On October 10, 2025, Corcept Therapeutics announced the termination of its Distribution Services Agreement with Optime Care, effective January 8, 2026. This decision follows a previous notification in June 2025, where Corcept exercised its rights to end Optime’s exclusivity in providing pharmacy services for its medications, impacting the company’s distribution strategy and potentially altering its market dynamics.
The most recent analyst rating on (CORT) stock is a Buy with a $82.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.
Spark’s Take on CORT Stock
According to Spark, TipRanks’ AI Analyst, CORT is a Outperform.
Corcept Therapeutics’ strong financial performance and positive earnings call sentiment are the primary drivers of its stock score. However, technical indicators suggest potential bearish momentum, and the high P/E ratio indicates overvaluation, which tempers the overall score.
To see Spark’s full report on CORT stock, click here.
More about Corcept Therapeutics
Corcept Therapeutics is a pharmaceutical company specializing in the development and commercialization of medications for the treatment of severe metabolic, oncologic, and psychiatric disorders. Its primary products include Korlym® and a generic mifepristone medication, focusing on specialty pharmacy distribution and patient support services.
Average Trading Volume: 855,159
Technical Sentiment Signal: Buy
Current Market Cap: $7.79B
See more insights into CORT stock on TipRanks’ Stock Analysis page.